Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

BACKGROUND: Prostate cancer is the most common cancer and second-leading cause of cancer death among men in the United States. Prostate cancer poses a large economic burden, which increases with progression from localized to metastatic disease. Newly approved treatments for non-metastatic castration...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Neil M., O’Day, Ken, Sugarman, Rebecca, Ramaswamy, Krishnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391103/
https://www.ncbi.nlm.nih.gov/pubmed/32020841
http://dx.doi.org/10.18553/jmcp.2020.19329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391103/
https://www.ncbi.nlm.nih.gov/pubmed/32020841
http://dx.doi.org/10.18553/jmcp.2020.19329

Ejemplares similares